[go: up one dir, main page]

TW200501978A - Use of FGF-18 in the diagnosis and treatment of memory disorders - Google Patents

Use of FGF-18 in the diagnosis and treatment of memory disorders

Info

Publication number
TW200501978A
TW200501978A TW092133218A TW92133218A TW200501978A TW 200501978 A TW200501978 A TW 200501978A TW 092133218 A TW092133218 A TW 092133218A TW 92133218 A TW92133218 A TW 92133218A TW 200501978 A TW200501978 A TW 200501978A
Authority
TW
Taiwan
Prior art keywords
fgf
treatment
diagnosis
memory
memory disorders
Prior art date
Application number
TW092133218A
Other languages
English (en)
Inventor
Sebastiano Cavallaro
Agata Velia D
Frank Dufour
Manickam Pachiappan
Daniel L Alkon
Original Assignee
Brni Neurosciences Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brni Neurosciences Inst filed Critical Brni Neurosciences Inst
Publication of TW200501978A publication Critical patent/TW200501978A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
TW092133218A 2002-11-26 2003-11-26 Use of FGF-18 in the diagnosis and treatment of memory disorders TW200501978A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42932102P 2002-11-26 2002-11-26

Publications (1)

Publication Number Publication Date
TW200501978A true TW200501978A (en) 2005-01-16

Family

ID=32393543

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092133218A TW200501978A (en) 2002-11-26 2003-11-26 Use of FGF-18 in the diagnosis and treatment of memory disorders

Country Status (6)

Country Link
US (1) US20040229292A1 (zh)
EP (1) EP1565204A1 (zh)
JP (1) JP2006516538A (zh)
AU (1) AU2003286285A1 (zh)
TW (1) TW200501978A (zh)
WO (1) WO2004047857A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112772560A (zh) * 2021-01-07 2021-05-11 昆明医科大学 一种秀丽隐杆线虫对病原细菌遗忘的动物模型的建立方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043234A1 (en) 1996-10-16 2005-02-24 Deisher Theresa A. Novel FGF homologs
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
WO2004032849A2 (en) 2002-10-07 2004-04-22 Zymogenetics, Inc. Methods of administering fgf18
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
EP2327413A1 (en) 2004-07-06 2011-06-01 ZymoGenetics, Inc. Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
US7858341B2 (en) 2004-12-10 2010-12-28 Zymogenetics, Inc. FGF18 production in prokaryotic hosts
KR101347100B1 (ko) 2005-07-29 2014-01-03 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 단독의 또는 pkc 억제제와 배합된 pkc 활성화제의 장기 기억 향상을 위한 용도
JP2007320940A (ja) * 2006-06-05 2007-12-13 Jichi Medical Univ 認知症治療剤、認知症治療方法、治療システム、治療装置
CA2673573C (en) 2007-02-09 2016-06-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
WO2008100449A2 (en) * 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
WO2008143880A2 (en) * 2007-05-24 2008-11-27 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury
WO2011035192A1 (en) * 2009-09-21 2011-03-24 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of gaba-b receptors to enhance neuronal function, learning and memory
JP6446624B2 (ja) 2010-07-08 2019-01-09 アルコン、ダニエル・エル. 脳卒中の治療法におけるpkc活性化因子および抗凝血剤
AU2016326689A1 (en) * 2015-09-24 2018-03-22 Genentech, Inc. Methods for the treatment of epilepsy
CN106070014B (zh) * 2016-06-15 2019-06-11 哈尔滨商业大学 一种基于水迷宫的动物学习记忆的个体化评价方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE493141T1 (de) * 1996-03-22 2011-01-15 Stryker Corp Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
JP5209161B2 (ja) * 1999-12-02 2013-06-12 ザイモジェネティクス, インコーポレイテッド 腺維芽細胞成長受容体−3又は−2を発現する細胞を標的化するための方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112772560A (zh) * 2021-01-07 2021-05-11 昆明医科大学 一种秀丽隐杆线虫对病原细菌遗忘的动物模型的建立方法

Also Published As

Publication number Publication date
EP1565204A1 (en) 2005-08-24
AU2003286285A1 (en) 2004-06-18
JP2006516538A (ja) 2006-07-06
US20040229292A1 (en) 2004-11-18
WO2004047857A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
TW200501978A (en) Use of FGF-18 in the diagnosis and treatment of memory disorders
Riba et al. Bringing ayahuasca to the clinical research laboratory
Backhaus et al. Test–retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia
Friedman et al. ERP components in picture matching in children and adults
Saletu et al. EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms: Comparative studies with remoxipride/haloperidol
WO2003075850A3 (en) Methods for alzheimer's disease treatment and cognitive enhancement
FI971955A7 (fi) Dopamineeristen solujen indusointi in vitro
WO2005046570A3 (en) Human stem cell materials and methods
DE60027415D1 (de) Zusammensetzung für die Verhinderung der Glattmuskelkrankheiten, die Ascorbat, Arginin und Magnesium enthält
Thunberg et al. Gender differences in facial reactions to fear-relevant stimuli
ATE353645T1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
EP2357223A3 (en) Human stem cell material and methods
TR199901304A2 (xx) Spiro $Piperidin-4,1'-Pirrolo $3,4-c]Pirrol ]
Zhou et al. Effects of viewing pleasant and unpleasant photographs on facial EMG asymmetry
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
Schik et al. Effect of aging on saccadic eye movements to visual and auditory targets
ATE538376T1 (de) Herstellung polyklonaler, monospezifischer antikörper gegen die upar-varianten del4, del5 und del4+5 sowie deren verwendung für diagnostische und therapeutische zwecke
HUP9701606A2 (hu) Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására
ATE110277T1 (de) Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen.
Konno et al. Effect of gum chewing on PFC activity during discomfort sound stimulation
ATE370416T1 (de) Neurosteroide als marker für die alzheimersche krankheit
RU94018755A (ru) Способ диагностики нарушения спинального кровообращения поясничного утолщения
HUP0102116A2 (hu) Paroxetin-aszkorbát, eljárás az előállítására és gyógyászati alkalmazása
Krystallis Systematic review of neuromuscular diurnal activity in restless legs syndrome
Shaheen et al. Effect of Caffeine Consumption on Sleep Quality of Health Professionals of Multan